Efficacy of nonestrogenic hot flash therapies among women stratified by breast cancer history and tamoxifen use: a pooled analysis.
Efficacy of nonestrogenic hot flash therapies among women stratified by breast cancer history and tamoxifen use: a pooled analysis.
复制标题
DOI：
10.1097/gme.0b013e31818c91ca
复制
发表时间：
2009-05
期刊：
影响因子：
--
通讯作者：
Loprinzi C
中科院分区：
文献类型：
--
作者：
Bardia A;Novotny P;Sloan J;Barton D;Loprinzi C
已发现各种非雌激素疗法可有效缓解潮热，但尚不清楚其疗效是否因女性是否患有乳腺癌和/或服用他莫昔芬而异。这项研究使用了来自马约诊所/北中央癌症治疗小组临床试验的数据，这些试验评估了任何非雌激素药物治疗潮热的疗效，并提供了乳腺癌病史或他莫昔芬使用的信息。使用Student t检验，使用个体患者数据评估第4治疗周与基线周相比的统计学显著变化。共有来自20项潮热研究的1,396名妇女有资格进行分析。总的来说，没有乳腺癌的女性在第4周的基线潮热评分百分比与乳腺癌相似（53% vs 50%，P = 0.92）。未服用他莫昔芬的妇女在第4周潮热评分的百分比显著低于服用他莫昔芬的妇女（54% vs 61%，P = 0.01）。然而，这是由于未接受他莫昔芬的女性中安慰剂组的潮热评分降低更高;随机安慰剂对照试验中活性治疗组第4周潮热评分较基线降低的百分比（即，不包括安慰剂组）在他莫昔芬使用者和非使用者之间相似（平均降低百分比差异为5.7; 95% CI为-1.76至13.16）。一些非雌激素治疗似乎是有用的减少潮热，无论潮热的病因。
Various nonestrogenic therapies have been found to be effective in mitigating hot flashes, but it has been unclear whether the efficacy varies by whether women have had breast cancer and/or were taking tamoxifen. This study used data from Mayo Clinic/North Central Cancer Treatment Group clinical trials that evaluated the efficacy of any nonestrogenic agent for hot flashes and had information on breast cancer history or tamoxifen use. Statistically significant changes from the fourth treatment week versus the baseline week, using individual patient data, were assessed using Student’s t test. A total of 1,396 women from 20 hot flash studies were eligible for analysis. Overall, women without breast cancer had a similar percentage of baseline hot flash score at week 4, as did those with breast cancer (53% vs 50%, P = 0.92). Women who were not taking tamoxifen had a significantly lower percentage of hot flash score at week 4 as compared with those who used tamoxifen (54% vs 61%, P = 0.01). However, this was due to a higher reduction in hot flash scores in the placebo arms among women not receiving tamoxifen; the percentage reduction in hot flash scores at week 4 from baseline in the active therapy arms of the randomized placebo-controlled trials (ie, excluding placebo arms) was similar among the tamoxifen users and nonusers (difference in mean percentage reduction, 5.7; 95% CI, −1.76 to 13.16). Some nonestrogenic therapies seem to be useful for reducing hot flashes, irrespective of the etiology of hot flashes.
登录
查看更多内容
DOI：
10.1097/gme.0b013e31817dfd2b
发表时间：
2009-01-01
影响因子：
2.7
作者：
Loprinzi, Charles L.;Barton, Debra L.;Wolf, Sherry
通讯作者：
Wolf, Sherry
影响因子：
45.3
作者：
Loprinzi, CL;Pisansky, TM;Perez, EA
通讯作者：
Perez, EA
影响因子：
45.3
作者：
Barton, DL;Loprinzi, CL;Novotny, P
通讯作者：
Novotny, P
DOI：
10.3816/sct.2006.n.022
发表时间：
2006-07-01
期刊：
Supportive cancer therapy
影响因子：
--
作者：
Bardia, Aditya;Thompson, Susan;Loprinzi, Charles L
通讯作者：
Loprinzi, Charles L
影响因子：
8.9
作者：
Loprinzi, CL;Barton, DL;Christensen, BJ
通讯作者：
Christensen, BJ